Alkermes plc, has announced that the U.S Food and Drug Administration has approved ARISTADA INITIO for the initiation of ARISTADA, a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. The ARISTADA INITIO regimen provides patients with relevant levels of aripiprazole within four days of initiation. The result is an alternative initiation regimen that gives healthcare providers an additional tool to support patients during a critical time in their treatment journey. St. Louis Clinical Trials, Woodland International Research Group, and Woodland Research Northwest congratulate Alkermes and are proud to have participated in this cutting-edge clinical trial.